Moderna, Inc. (MRNA) News

Moderna, Inc. (MRNA)

Today's Latest Price: $71.28 USD

5.54 (8.43%)

Updated Oct 29 6:55pm

Add MRNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

Filter MRNA News Items

MRNA News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest MRNA News From Around the Web

Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…

PR Newswire | October 2, 2020

Coronavirus tracker: AstraZeneca's vaccine trial restarts in Japan; Moderna CEO eyes Thanksgiving vaccine filing

AstraZeneca's vaccine trial resumed in Japan but its U.S. is still on hold. Moderna aims to file for an emergency nod on Nov. 25, CEO Stéphane Bancel said. The FDA expanded its emergency green light for Access Genetic's OraRisk test. An HHS pandemic messaging campaign hit snags. And President Trump has tested positive for COVID-19.

FiercePharma | October 2, 2020

Experts weigh in after poll shows only 2 in 10 Americans will take COVID-19 vaccine Trump deems safe

Filed under: News , Drugs & Medicine , Science & Tech Despite positive news from both Moderna and Johnson & Johnson this week on their vaccine trials, a new poll from Axios-Ipsos found that “barely two in 10 Americans” would take a COVID-19 vaccine if President Trump declared it safe. In comparison, 62 percent said they would take it if their doctors declared it safe and 54 percent would take it if the Food and Drug Administration deemed it safe. Read more… Permalink | Email this | Linking Blogs | Comments

AOL | October 1, 2020

Moderna chief says Covid-19 vaccine won't be widely available before late March

If Moderna's coronavirus vaccine is proven safe and effective, the general population could have access to it by late March or early April next year, Moderna CEO Stéphane Bancel said on Wednesday.

CNN | October 1, 2020

Will October Be A Reachable Goal For A Vaccine?

Despite slim chances that the COVID-19 vaccine will see the light of the public day in October, Pfizer Inc. (NYSE: PFE ) is getting our hopes up. According to SVB Leerink, a Wall Street firm, even though Moderna Inc (NASDAQ: MRNA ) and Pfizer began their trials on the same day, Pfizer's is built for speed. As a reminder, there are four vaccines undergoing the final stage of U.S. clinical trials and a fifth by Maryland-based Novavax, Inc. (NASDAQ: NVAX ) on the way. Although the final stage of clinical trials in the U. S. will begin in October Phase 3 in the UK is well underway as of September 25 th . The four other candidates besides Moderna and Pfizer are Johnson & Johnson (NYSE: JNJ ) and AstraZeneca plc (NYSE: AZN ). But unlike Johnson & Johnson and AstraZeneca which have said they w...

Benzinga | October 1, 2020

Moderna To Not Seek FDA COVID-19 Vaccine Approval Until After US Election

Moderna Inc (NASDAQ: MRNA ) CEO Stéphane Bancel scuttled hopes that a COVID-19 vaccine from the drugmaker would be available before the presidential election takes place in the United States in an interview with the Financial Times published Wednesday. What Happened: Bancel told FT that the Massachusetts-based company would not be in a position to seek emergency use authorization for the jab from the Food and Drug Administration before the end of November. “November 25 is the time we will have enough safety data to be able to put into a EUA file that we would send to the FDA — assuming that … Full story available on Benzinga.com

Benzinga | October 1, 2020

Moderna's coronavirus vaccine won't be ready for widespread distribution until spring, CEO predicts

The timeline regarding a coronavirus vaccine was a hot topic of Tuesday night's presidential debate.

Fox News | October 1, 2020

American, United, Goldman Sachs, Moderna - 5 Things You Must Know Thursday

Stock futures rise on signs of progress toward a coronavirus aid package; American and United begin furloughs of 32,000 employees; Goldman Sachs resumes job cuts.

The Street | October 1, 2020

COVID-19 'Phase 3' Vaccine Trial Participants Report Day-Long Migraines, Fever

COVID-19 'Phase 3' Vaccine Trial Participants Report Day-Long Migraines, Fever Tyler Durden Thu, 10/01/2020 - 09:05 European press reports earlier indicated that the EU's pharma regulator is preparing to expedite approval of the AstraZeneca-Oxford vaccine, even as the FDA expands its investigation into the COVID-19 vaccine's Phase 3 trials (after a patient was reportedly seriously sickened in the UK, though AZ insists that illness had nothing to do with the trial). As the WHO, Bill Gates, Dr. Fauci and the global health-care establishment work with their allies in the press to try and convince as many people as possible to agree to take a COVID-19 vaccine once one is approved, more alarming reports are emerging in the mainstream press about issues with the 'Phase 3' trials. CNBC reporte...

Zero Hedge | October 1, 2020

Volunteers in covid vaccine trials describe painful side effects

Luke Hutchinson, 44, volunteered to participate in Moderna's coronavirus vaccine trial. He developed a fever, aches that left him bedridden for the day and with chills so bad he cracked a tooth.

Daily Mail Online | October 1, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4786 seconds.